Gonadorelin
- Category
- Hormone & Sexual Health
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A synthetic form of GnRH, well studied for triggering LH and FSH release to induce ovulation and test pituitary function. Its trendy longevity-clinic use, preserving testicular function during TRT, is speculative and unproven in humans. The key risk is dosing: continuous, non-pulsatile use paradoxically shuts down the axis it's meant to stimulate, and rare anaphylaxis is reported. Not FDA-approved for that use; supply is compounded or research-grade.
Read Full recordStudied uses & evidence
Studied uses(6)
Stimulates endogenous LH and FSH production
HighReproducible, dose-dependent LH and FSH rise in humans, basis of an FDA-approved diagnostic test.
Induces ovulation in hypothalamic amenorrhea
HighApproved therapy; pulsatile dosing produced ovulation in about 94-96% of women in clinical trials.
Stimulates spermatogenesis in hypogonadotropic hypogonadism
MediumPulsatile GnRH pump therapy induced sperm production in about 61% of men in a 2024 study.
Evidence limits
- Evidence Level
- Level 1-2 — Strong
Gonadorelin has decades of Level I-II evidence for ovulation induction in hypothalamic amenorrhea and spermatogenesis induction in hypogonadotropic hypogonadism. The diagnostic GnRH stimulation test is a well-validated clinical tool. Its use as an HCG alternative in TRT protocols is supported by mechanistic rationale and clinical experience but lacks large randomized controlled trials.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Hormone-sensitive cancers (prostate, breast)
HighInitial LH/FSH surge can temporarily increase sex hormone levels before suppression.
General cautions
Pregnancy
AbsoluteCan disrupt pregnancy hormones.
Risk summary(13)
Risks = level of concern: High · Moderate · Low · Theoretical
Headache, nausea, lightheadedness, and abdominal discomfort (uncommon)
LowInjection site reactions including pain, swelling, induration, and pruritus
LowHypersensitivity/anaphylactic reactions (rare but reported; caution on re-administration)
ModerateFlushing and tachycardia (rare)
LowBronchospasm (rare)
LowMultiple pregnancy risk when used for ovulation induction (12% incidence in clinical trials)
HighOvarian hyperstimulation syndrome (rare, especially with concurrent clomiphene)
LowAntibody formation with repeated administration (rare)
LowRisk of pituitary apoplexy if administered to patients with undiagnosed pituitary adenoma
LowMenorrhagia (frequency unknown)
TheoreticalParadoxical pituitary downregulation with continuous (non-pulsatile) high-dose administration
HighPotential worsening of hormone-dependent tumors due to initial gonadotropin surge
TheoreticalSkin allergic reactions at pump infusion site (noted in pulsatile pump studies)
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.